Our clinical trials are evaluating the safety and efficacy of MultiVir’s investigational cancer treatments called “Tumor Suppressor Immune Gene Therapy” and “Dendritic Cell Therapeutic Vaccines”.

Tumor suppressor p53 and IL24 gene abnormalities are among the most common molecular defects in cancers causing tumor progression, treatment resistance and immune suppression.

MultiVir’s Ad-p53 and Ad-IL24 Tumor Suppressor Immune Gene Therapy product candidates deliver normal p53 and IL24 genes into tumors to restore their tumor suppressor functions which include inhibition of tumor growth and the activation of anti-tumor immune responses.

MultiVir’s Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad.p53-DC) is an investigational immuno-stimulatory therapy designed to activate the immune system to attack tumor cells.

Active Clinical Trials

Planned Clinical Trials





If you are interested in learning more about our clinical trial programs or enrolling a patient, please complete the form below and click “submit.”

You should hear from us within 1-2 business days and thank you for your interest in our clinical programs. We very much appreciate each of our wonderful patients who participate in our studies and the medical professionals who refer them!